Adriamycin
(doxorubicin hydrochloride)Phase 3Small molecule
PfizerDoxorubicin is a chemotherapy drug used to treat various cancers including breast cancer, lymphomas, and leukemias by killing rapidly dividing cancer cells throughout the body.[1] Adriamycin is currently being investigated across 55 indications[3], with its most advanced program in Phase 3.[1]
Adriamycin is one of 699 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 3.
55
Indications
555
Total Trials
12
Active Trials
698
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 55 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma37 trials
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Active, not recruiting·—·Phase 1·NCT02337985·10 enrolled
Show 34 more trials
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00379041·1,158 enrolled
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT00060385·3 enrolled
Breast Cancer31 trials
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Completed·—·Phase 2·NCT00003953·39 enrolled
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
Completed·—·Phase 2·NCT00003042·41 enrolled
Show 28 more trials
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Terminated·—·N/A·NCT01897441·31 enrolled
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
Active, not recruiting·—·Phase 2·NCT00295893·121 enrolled
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
Withdrawn·—·Phase 1·NCT00074139
Acute Lymphoblastic Leukemia16 trials
Show 13 more trials
Soft Tissue Sarcoma10 trials
Show 7 more trials
A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
Unknown status·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·NCT05138146·70 enrolled
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003212·780 enrolled
Neuroblastoma10 trials
Show 7 more trials
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
Completed·—·Phase 3·NCT00002802·500 enrolled
44 more indications
Mantle Cell Lymphoma8 trials
Hodgkin's Disease8 trials
Show 5 more trials
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000626·27 enrolled
Leukemia5 trials
Endometrial Cancer5 trials
Kaposi's sarcoma4 trials
Prostate Cancer4 trials
Advanced Cancer4 trials
Multiple Myeloma4 trials
Liver Cancer3 trials
Diffuse Large B-Cell Lymphoma3 trials
Anaplastic Large Cell Lymphoma3 trials
Osteosarcoma3 trials
Liposomal Doxorubicin3 trials
Bone Marrow Transplantation3 trials
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1/2·NCT00003086·12 enrolled
Rhabdomyosarcoma3 trials
Radiation Therapy2 trials
Kidney Cancer2 trials
Stem Cell Transplantation2 trials
Bladder Cancer2 trials
Transitional Cell Carcinoma1 trial
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00028756·285 enrolled
Ewing sarcoma1 trial
Chemotherapy1 trial
Refractory Solid Tumors1 trial
Head and Neck Cancer1 trial
Safety and Efficacy1 trial
Lung Cancer1 trial
Primitive Neuroectodermal Tumor1 trial
Urothelial Cancer1 trial
Uterine Leiomyosarcoma1 trial
Mesothelioma1 trial
Newly Diagnosed1 trial
Classic Hodgkin Lymphoma1 trial
Patients With Solid Tumors1 trial
T-cell non-Hodgkin lymphoma1 trial
Ovarian Cancer1 trial
Relapsed or Refractory1 trial
Immunosuppression1 trial
Thyroid Cancer1 trial
Locally Advanced1 trial
B-cell acute lymphoblastic leukemia1 trial
Adenoid Cystic Carcinoma1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
DOXORUBICIN HYDROCHLORIDE
NDA NDA050467
Dec 23, 1987
DOXORUBICIN HYDROCHLORIDE
NDA NDA050629
Nov 17, 1995
DOXIL (LIPOSOMAL)
NDA NDA050718
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for doxorubicin hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]